News
-
-
PRESS RELEASE
As the Ebola Epidemic Spreads, NV-387 Oral Gummies Can Enter a Phase II Clinical Trial for Treatment of Ebola - NanoViricides Proposal is Approved by the Pillar Committee in DR Congo
NanoViricides, Inc. receives approval for Phase II Clinical Trial of NV-387 Oral Gummies as Treatment for Bundibugyo Ebolavirus in DR Congo, addressing lack of effective Ebola treatments -
-
PRESS RELEASE
As the Ebola Emergency Outbreak Grows Rapidly, NanoViricides Has Proposed a Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment - with Superior Oral Administration and Escape Resistance Features Over Antibodies
NanoViricides, Inc. proposes Phase II Trial of NV-387 Oral Gummies for Bundibugyo Ebolavirus. Potential treatment for current outbreak, offering oral delivery of broad-spectrum antiviral drug -
-
PRESS RELEASE
In the Ebola Emergency, NV-387 is Ready to be Shipped to DRC, and It Compares Favorably as a Treatment for Ebola Versus Possible Options, Says NanoViricides
NanoViricides, Inc. announces potential treatment option for Ebola Bundibugyo virus strain, highlighting broad-spectrum antiviral drug candidate NV-387, superior to Remdesivir, ready for Phase II clinical trial -
-
-
-
PRESS RELEASE
Ebola Global Health Emergency Needs a Broad-Spectrum Drug - NV-387 is a Strong Potential Candidate, Says NanoViricides
NanoViricides, Inc. highlights the urgent need for a broad-spectrum antiviral drug like NV-387 amid an Ebolavirus outbreak in DR Congo and Uganda. NV-387 holds promise as it targets sulfated proteoglycans crucial for viral attachment to cells
